Bavarian Nordic Bidders Extend Offer Deadline, Maintain Price

Nordic Capital and Permira have extended the deadline for their 233-krone per share takeover bid for Bavarian Nordic A/S until October 14, citing the need for final regulatory approval. The private equity firms are maintaining their original offer price despite pushback from key investors regarding the valuation, signaling a firm stance on their proposed acquisition terms amidst ongoing regulatory processes.

Analysis

The takeover bid for Bavarian Nordic A/S by private equity firms Nordic Capital and Permira is entering a critical phase, marked by a two-week extension of the offer period to October 14. While the extension is officially to secure final regulatory approval, the bidders' decision to maintain their 233-krone per share offer is significant. This price is being held firm despite explicit pushback from key investors who contest the valuation of the Danish vaccine maker. This signals a disciplined, and potentially final, offer from the acquirers, creating a standoff between their valuation and that of dissenting shareholders. The outcome of the bid now appears contingent on both the final regulatory green light and the ability of the private equity pair to secure sufficient shareholder acceptance at the current price before the new deadline.

Key Decisions for Investors

• Existing shareholders face a clear decision point ahead of the October 14 deadline: accept the 233-krone per share offer or risk the deal failing, which could remove the bid premium and potentially re-price the stock lower.
• M&A arbitrageurs should note the elevated risk profile; while the extension for regulatory approval is a procedural step, the primary risk is shareholder rejection, making it crucial to monitor institutional investor statements and share price movements relative to the offer price.
• Investors should consider that the bidders' firm stance on the 233-krone price establishes a potential near-term ceiling for the stock, with downside risk tied to the company's standalone valuation should the acquisition fail.